BiotechGuyNYC

Following (and questioning) the biotech universe

[BiotechGuyNYC @abishackmtl]

@MindreaderBio Challenging to be first line with Oma biosimilars

[Sri Kosuri @srikosuri]

Today, there's a strong focus on fast-follows of existing drugs. The drug programs that inspire me look different – the target is known, but we don't know how to build the drug, often requiring the dev of new tech that paves the path for more drugs. https://t.co/Vgk3sfysQc

[BiotechGuyNYC @abishackmtl]

@BiotechObserver @AppleHelix Curious how robust the hypothesis of blocking oxIL-33 is. Nice paper from AZN, but has not been broadly validated.

[BiotechGuyNYC @abishackmtl]

@Archimedes20311 These results were for their X2 though?

[BiotechGuyNYC @abishackmtl]

@Archimedes20311 @john_hersc79276 Think the TYK2 potency could be important here (high IL-12 / IL-23) vs the JAK1 inhibitors

[BiotechGuyNYC @abishackmtl]

@Archimedes20311 A me-too of what?

[Sid Sijbrandij @sytses]

My cancer case is n=1. I'm not holding it up as a model, because most of what I did is not specifically replicable or scaleable. But it is a proof of concept that fully personalized medicine, built around one patient's own biology, is viable in ways it simply wasn't a few years ago. I have lived a version of the future of cancer care that I think is worth aspiring to more broadly.

Many of the tools that made this future possible for me are getting better, faster, cheaper, and more accessible every year. I think what we need next is the infrastructure to deploy these tools, and the community willing to build this infrastructure, one patient at a time.

I want to help that future arrive faster. I wrote an article in The Cancer Letter https://t.co/ejel0unTvr for the physicians and researchers closest to the patients who could benefit most from this approach, who also believe in this future. If you are working towards building the systems and practices that will make personalized medicine operationally real, we want to collaborate with you too.

[Martin Borch Jensen @MartinBJensen]

Learning biotech, part 5:
What does every independent commercial biotech have in common?
Striking at least one major pharma deal in their first decade.

Why would you do this?
It takes hundreds of millions of dollars to get to an approved drug, and raising that amount of capital can be challenging.
Part 4 taught us that confidence = value in biotech. This cuts both ways: increasing people's confidence in your endeavor increases its value. And for investors, a major pharma spending time and money working with you means both that there's a market for your product, and (hopefully) that they've diligenced your science.
So a partnership both extends your runway, letting you derisk more, and typically decreases how much of the company you'll have to sell at your next financing.

So how does this work?
Your first stop should be @CRISPR_LuCas' great intro:
✍️ https://t.co/O6NVuNH3Zi

@JorgeCondeBio and @beckypferdehirt also did a very nice overview of the elements of a deal and how to think about them:
✍️ https://t.co/fnjYUD9Kim

At this point, consider what you are willing to give up in a partnership. If you have only one program and give up most its future revenue, your company's value goes way down.
The ideal scenario is that 1) you have a versatile technology for discovering or delivering targets across multiple diseases, and can partner only on one of these, and 2) the partnership gives you enough revenue to do a lot of internal work in addition to executing the partnership.

If you haven't already, read 📚 “Genentech: The Beginnings of Biotech,” by Sally Smith Hughes.
Genentech had a platform (cloning and making proteins), and managed multiple deals before they started to make their own drugs.
And go back to the others books recommended in this thread, and notice how often a partnership was the lifeblood needed to make progress.
@ElliotHershberg and @patricksmalone also wrote a nice blog post: ✍️ https://t.co/iDiNXdC4HZ

To make deals happen, you need: to have proprietary IP or capabilities, meet group leaders whom you can help and get them excited, make sure there's leadership support for a deal, then hash out a win-win scope (over many months, typically).
Fundamentally, this is like other complex B2B sales, so you can draw general lessons from good frameworks like this: ✍️https://t.co/EVMNCwnS4o
The main difference is that your champion will be strongly guided by the science, so you need to show rigor and data.

For more insight into the pharma side perspective, ✍️ Juen Cueva's substack is a nice overview of the basics: https://t.co/kJqQ21MIG7
And this short perspective from Roche adds flavor: 📰 https://t.co/3hzq0o2VPI

A few intro resources for how to prepare your hunt:
✍️ https://t.co/aNVuWBsTHh
✍️ https://t.co/LUsVgptjMg

For how to negotiate the license, here's an overview of what to think about:
✍️ https://t.co/wkz5bXitVC
You'll also want to understand what pharma paid for similar deals. Goodwin has an annual overview https://t.co/qafw17MYn0, and you should look up everything that happened in the last several years.
Important to note that the stage of the deal (discovery versus mature molecule vs clinical) makes a big different, but so does the indication area and other factors.

Finally, the grand champion of pharma partnerships was Millenium Pharmaceutical. If you want to learn from the best, there are a few written accounts:
From their CBO: https://t.co/NdCRxMflCh
and if you're willing to pay for an HBS case study:
https://t.co/j85rVOzVdi

Happy hunting!

[BiotechGuyNYC @abishackmtl]

@Archimedes20311 Blame whatever consultants they hired…

[BiotechGuyNYC @abishackmtl]

@Archimedes20311 @plainyogurt21 Pursuing chronic indications with unnecessary CNS penetration… what could go wrong??

[Biotech "2020 2: This Time With Feeling" Mongoose @BiotechMongoose]

Me running my shitty robots in an open-air warehouse without apparently any hepa filters on the air vents: oh yeah, this is the robotic drug discovery factory of the future

[alli @sonofalli]

“nothing from my end thanks”

[Randalls Island Park @randallsisland]

Dolphin sighting here at Randall’s Island Park! #dolphins #dolphinwatching 🐬

[mariana Z @mariana057]

The older I get, the more I understand why roosters just wake up and scream.

[BiotechGuyNYC @abishackmtl]

@alexolim_ Organic

[BiotechGuyNYC @abishackmtl]

@chddaniel @claudeai SHIP

[BiotechGuyNYC @abishackmtl]

@PrajwalTomar_ @Lovable Lovable

[Byrne Hobart @ByrneHobart]

To put this in perspective, it's roughly 4.9m Turkish Airlines miles.

[one dozen rats at a keyboard @PanasonicDX4500]

day two in Zohran Mamdani’s New York. I watched a gaggle of financial analysts get ziptied and marched into an unmarked van. A man ordered a latte with whole milk in front of me in line and the barista immediately shot him in the head.

[lada @ladanuzhna]

Biotechs would say stuff like "we can't raise money" but founder still has 2 kidneys. Curious.